The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout

By sjmartinez • March 12, 2024

Yokose C, McCormick N, Abhishek A, Dalbeth N, Pascart T, Lioté F, Gaffo A, FitzGerald J, Terkeltaub R, Sise ME, Januzzi JL, Wexler DJ, Choi HK. The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024 Mar 12. doi: 10.1038/s41584-024-01092-x. Epub ahead of print. PMID: 38472344.

Tags: Publications, Rheumatology, Veterans Administration

Genetic Research within Indigenous Communities: Engagement Opportunities and Pathways Forward

Barton KS, Porter KM, Mai T, Claw KG, Hiratsuka VY, Carroll SR, Burke W, Garrison NA. Genetic Research within Indigenous Communities: Engagement Opportunities and Pathways[...]

Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study

Rastogi A, Pollack CV Jr, Sánchez Lázaro IJ, Lesén E, Arnold M, Franzén S, Allum A, Hernández I, Murohara T, Kanda E. Maintained renin-angiotensin-aldosterone system[...]

A Tale of Two Islands – Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights

Haake DA. A Tale of Two Islands - Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights. Am J Trop Med Hyg. 2024 May 2:tpmd240254.[...]